[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"her2-positive-advanced-gastric-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:her2-positive-advanced-gastric-cancer":74},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100515571","a-study-of-trastuzumab-deruxtecan-for-patients-with-advanced-her2-positive-gastric-or-gastroesophageal-junction-adenocarcinoma-who-have-received-a-prior-trastuzumab-based-regimen-accompanied-by-a-disease-registry-of-patients-treated-with-conventional-therapies-prosperity-100515571",false,"NCT05993234","A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)","A Prospective Non-interventional Study (NIS) of Trastuzumab DeRuxtecan (T-DXd) for Adult Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction (GEJ) AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen, Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies in a Real-world Setting in Europe (PROSPERITY)","Inclusion Criteria:\n\n* Male or female adult patient (age ≥ 18 years) with HER2 + advanced gastric or GEJ adenocarcinoma who have received a prior trastuzumab based regimen\n* Histological or cytological confirmed diagnosis of advanced HER2 positive gastric cancer or GEJ\n* Documented HER2 + status (archival sample or recent sample prior 2L therapy)\n* Decision to newly initiate monotherapy T-DXd or conventional therapies per SMPC according to the physician's choice\n* Written dated and signed Informed Consent (ICF) to participate in the study\n\nExclusion Criteria:\n\n* Patients who at time of data collection for this study are participating in or have participated in an interventional study that remains blinded\n* Pregnancy or breastfeeding\n\nNo specific exclusion criteria are defined, as patients will be treated according to the proposed indication statements in the SmPC.","ALL","18 Years",{"count":19,"type":20},257,"ESTIMATED","2 Years","OBSERVATIONAL","Trastuzumab deruxtecan (T-DXD) as monotherapy is indicated for the treatment of adult patients with advanced HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.\n\nThis study will assess the effectiveness of T-DXd, patient demographic and clinical characteristics, and treatment patterns in patients with advanced HER2-positive advanced gastric or GEJ adenocarcinoma.",[25,26],"HER2-positive Advanced Gastric Cancer","HER2-positive Gastroesophageal Junction Adenocarcinoma",[25,26,28,29,30],"Trastuzumab Deruxtecan","Conventional therapy","ENHERTU®","RECRUITING","2026-05-05",{"date":34,"type":35},"2026-05-08","ACTUAL",{"date":37,"type":35},"2023-12-05",{"date":39,"type":20},"2027-09-01",{"name":41,"class":42},"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","INDUSTRY",76,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100488493","phase-1-trastuzumab-bevacizumab-with-paclitaxel-for-her2-positive-gastric-cancer-in-a-second-line-therapy-100488493","NCT05640830","Trastuzumab, Bevacizumab with Paclitaxel for HER2-positive Gastric Cancer in a Second-line Therapy","A Phase 1B\u002F2 Study of Trastuzumab, Bevacizumab with Paclitaxel for HER2-positive Gastric Cancer in a Second-line Therapy (TREAZURE)","TREAZURE","Inclusion Criteria:\n\n1. HER2-positive advanced gastric cancer\n\n   * Defined as IHC 2+, which is IHC 3+ or SISH + (or FISH) evaluated by laboratory tests. (SISH positivity is defined as the ratio of the HER2 gene copy number to the CEP17 signal ≥ 2.0)\n   * or significant overexpression of HER2 protein on target proteomic analysis (multiple reaction monitoring)\n2. Patients who have progressed in response to one systemic anticancer therapy for advanced gastric cancer\n3. Patients who are willing and able to write a written consent form for this trial.\n4. Patients aged 19 years or older at the time of signing the subject consent form.\n5. Patients with measurable or evaluable lesions according to RECIST 1.1.\n6. ECOG activity status 0, 1 or 2\n7. as patients with adequate organ function\n\n   * Absolute neutrophil (ANC) ≥1.0 x 109\u002FL, platelet ≥100 x 109\u002FL, hemoglobin ≥9 g\u002FdL, serum creatinine ≤1.5 x ULN, total bilirubin ≤3.0 mg on laboratory tests within 2 weeks before starting treatment \u002FdL, AST\u002FALT ≤5 x ULN\n   * Echocardiogram EF ≥55% or MUGA scan ≥50%\n\nExclusion Criteria:\n\n1. Patients who have received chemotherapy, radiation therapy, immunotherapy or targeted therapy for gastric cancer within the past 2 weeks.\n2. Patients who have experienced Grade 3-4 gastrointestinal bleeding within 3 months\n3. Patients who have experienced an arteriovascular embolism event, including but not limited to myocardial infarction, transient ischemic attack, cerebrovascular disorder, or unstable angina within 6 months\n4. Ongoing or active infection, symptomatic congestive heart failure, unstable angina, symptomatic or poorly controlled cardiac arrhythmias, uncontrolled thrombotic or hemorrhagic disorders, or any other serious medical disorder not controlled in the investigator's judgment patient with\n5. Patients with a history of gastrointestinal perforation or fistula within 6 months.\n6. Concomitant diagnosis of cancer in another site or history of active malignant tumor within the past 3 years\n\n   * Excluding fully cured basal cell carcinoma and thyroid cancer, in situ cervical cancer",{"count":53,"type":20},47,"INTERVENTIONAL",[56,57],"PHASE1","PHASE2","This is a multicenter, open-label, prospective, phase 2 study of trastuzumab, bevacizumab, and paclitaxel as second-line treatment for patients with HER2-positive advanced gastric cancer who had progressed on first-line chemotherapy including trastuzumab or anti-HER2 agents.",[25],[61,62],"HER2-positive gastric cancer","trastuzumab, bevacizumab & paclitaxel","2024-11-23",{"date":65,"type":35},"2024-11-26",{"date":67,"type":35},"2023-01-01",{"date":69,"type":20},"2026-12-31",{"name":71,"class":72},"Kangbuk Samsung Hospital","OTHER",1,"HER2 Positive Advanced Gastric Cancer"]